Skip to main content
    I

    Iradimed Co (IRMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $83.45
    -1.39 (-1.64%)

    Market Cap: $1.09B

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Iradimed Co (IRMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Iradimed (IRMD) has a market cap of $1.09B and an enterprise value of $1.03B. Its trailing P/E is 42.8x.

    Total Valuation

    Enterprise value is 5.80% below the market cap, as cash exceeds debt.

    Market Cap$1.09B
    Enterprise Value$1.03B
    Latest price (Nov 17, 2026)$83.45

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 13, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateOct 30, 2026
    Last Ex-Dividend DateNov 13, 2026
    Next Payment DateNov 27, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.02% in the quarter ended Sep 30, 2026 and grew 0.46% a year over 2 years.

    Shares Outstanding12.79M
    Shares Change (YoY)+0.52%
    Shares Change (QoQ)+0.02%
    Share Count Growth (2Y CAGR)+0.46%

    Valuation Ratios

    Sales and book value multiples are 11.9x and 10.0x. Its year-end P/E ranged from 15.9x to 72.1x from 2016 to 2025.

    P/E Ratio42.8x
    Forward P/E39.0x
    P/S Ratio11.9x
    Forward P/S11.8x
    P/B Ratio10.0x
    P/TBV Ratio10.4x
    P/FCF Ratio41.0x
    P/OCF Ratio40.2x
    PEG Ratio3.8

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 30.6x EBITDA and 38.6x free cash flow.

    EV / Earnings42.9x
    EV / Sales11.5x
    EV / EBITDA30.6x
    EV / EBIT33.0x
    EV / FCF38.6x

    Price Statistics

    The stock is down 0.11% over 52 weeks and trades 1.96% below its 50-day average.

    Beta (1Y)0.73
    52-Week Change-0.11%
    1-Month Change-4.57%
    3-Month Change-4.30%
    6-Month Change-4.26%
    5-Year Change+105.47%
    10-Year Change+711.43%
    Total Return (1Y)+1.44%
    Total Return (3Y CAGR)+27.33%
    Total Return (5Y CAGR)+19.06%
    Return vs SPY (1Y)-13.79%
    Max Drawdown (1Y)-27.05%
    Max Drawdown (3Y)-27.05%
    Sharpe Ratio (1Y)-0.07
    Correlation with SPY (1Y)0.32
    50-Day Average$85.12
    200-Day Average$91.30
    52-Week Range$76.17 to $106.95
    RSI (14 Days)45.3
    Average Volume (20 Days)131.05K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 8.99x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio8.99x
    Quick Ratio7.68x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 22.53% over the last 12 months, against a 5-year average of 20.06%.

    Return on Equity (ROE)22.53%
    Return on Assets (ROA)19.81%
    Return on Capital Employed (ROCE)28.10%
    ROE (5Y Average)20.06%
    ROA (5Y Average)17.03%
    ROIC (5Y Average)22.96%
    Asset Turnover0.76x
    Inventory Turnover1.70x
    Receivables Turnover6.65x
    Cash Conversion Cycle234 days

    Taxes

    Income tax took 22.92% of pretax income over the last 12 months.

    Income Tax (TTM)$7.13M
    Effective Tax Rate22.92%

    Scores

    IRMD has an Altman Z-Score of 47.06, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score47.06
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $89.34M over the last 12 months is up 10.97% from the 12 months before.

    Revenue$89.34M
    Revenue Growth (YoY)+10.97%
    Gross Profit$67.46M
    Operating Income$28.86M
    Pretax Income$31.12M
    Net Income$23.98M
    EBITDA$32.77M
    EBIT$31.12M
    Reported EPS (TTM)$1.95

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 87.92% of the $121.07M in total assets.

    Cash and Equivalents$63.29M
    Total Debt$0
    Net Cash$63.29M
    Net Cash Per Share$4.95
    Working Capital$82.48M
    Shareholder Equity$106.45M
    Book Value Per Share$8.33
    Tangible Book Value$103.04M
    Tangible Book Per Share$8.06
    Total Assets$121.07M
    Total Liabilities$14.62M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.13M of capital spending, operating cash flow left $26.02M of free cash flow.

    Operating Cash Flow$27.15M
    Capital Expenditures$1.13M
    Free Cash Flow$26.02M
    FCF Per Share$2.03
    Depreciation and Amortization$1.66M
    Dividends Paid$16.23M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 32.30%, against a 5-year average of 28.91%.

    Gross Margin75.51%
    Operating Margin32.30%
    Pretax Margin34.83%
    Net Margin26.85%
    EBITDA Margin36.68%
    EBIT Margin34.83%
    FCF Margin29.12%
    Gross Margin (5Y Average)76.86%
    Operating Margin (5Y Average)28.91%
    Net Margin (5Y Average)25.13%

    Growth

    Revenue grew 16.28% a year over 3 years, and EPS 20.77% a year.

    Revenue Growth (3Y CAGR)+16.28%
    Revenue Growth (5Y CAGR)+21.45%
    EPS Growth (3Y CAGR)+20.77%
    EPS Growth (5Y CAGR)+36.18%
    FCF Growth (3Y CAGR)+26.48%
    FCF Growth (5Y CAGR)+26.11%
    Operating Income Growth (3Y CAGR)+18.72%
    Book Value Per Share Growth (2Y CAGR)+14.49%
    Tangible Book Per Share Growth (2Y CAGR)+14.46%

    Revenue and profit by year

    Dividends and Yields

    IRMD pays out 42.65% of earnings as dividends.

    Dividend Per Share (Annual)$0.80
    Dividend Yield0.96%
    Payment ScheduleQuarterly
    Payout Ratio42.65%
    FCF Payout Ratio62.37%
    Earnings Yield2.34%
    FCF Yield2.44%
    Shareholder Yield1.52%

    Full dividend history

    Peer Position

    Against 9 similar companies, IRMD has the 2nd highest P/E.

    P/E Ratio42.8x vs 11.5x median
    P/S Ratio11.9x vs 1.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+10.97% vs +4.29% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 10.50% and EPS growth at 12.65% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+10.50%
    EPS Growth Forecast (2Y CAGR)+12.65%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IRMD

    What is IRMD's market cap?

    Iradimed has a market cap of $1.09B. Its enterprise value, which adds debt and subtracts cash, is $1.03B.

    What is IRMD's P/E ratio?

    Iradimed has a trailing P/E ratio of 42.8x and a forward P/E of 39.0x.

    How many shares of IRMD are outstanding?

    Iradimed has 12.79M shares outstanding. The count is up 0.52% from a year earlier.

    Does IRMD pay a dividend?

    Yes. Iradimed pays $0.80 a share a year, a dividend yield of 0.96%.

    How much debt does IRMD have?

    Iradimed has $0 of total debt and $63.29M of cash and equivalents, a net cash position of $63.29M.